Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00247689 · ClinicalTrials.gov registry record

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Terminated
Registry status
31
Enrollment target

NCT00247689: Clinical Trial study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00247689 is a clinical trial that was terminated before completion, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00247689 was terminated before completion, sponsored by National Institute on Drug Abuse (NIDA).

TERMINATED
Registry status
31 participants
Enrollment target

Study Summary

Background: * Research has shown that several human genes have been associated with vulnerability to substance abuse and dependence. However, little is known about how people with these genetic tendencies react to drugs in controlled settings. * Methylphenidate, also known as Ritalin, is commonly prescribed for a number of conditions, including attention deficit disorder. Because methylphenidate is widely used in studies of brain chemistry and behavior and has relatively low risks associated with it use, researchers are interested in seeing how it affects the thinking processes of people with apparent genetic vulnerability to drug abuse. Objectives: \- To evaluate whether individuals with apparent genetic vulnerability to drug abuse react differently to methylphenidate than people who do not have this vulnerability. Eligibility: \- Individuals at least 18 years of age or older who have participated in the NIDA protocol Allelic Linkage in Substance Abuse. Design: * Participants will be asked to avoid using a number of over-the-counter medications, including antihistamines, cough medicines, and nasal decongestants, for 24 hours before the study day. Participants will also be asked to avoid consuming caffeinated beverages, nicotine or tobacco products, or alcohol on the morning of the day of the study, and will provide a urine sample at the start of the study to be tested for chemicals that may interfere with the study. * Because of the nature of the study drug, participants will not be allowed to drive to the clinical center on the day of the study. (Return transportation will be arranged.) * At the start of the study, participants will take two tablets (each 1 hour apart), and will not be told whether the tablets are the study drug or a placebo. * Participants will give regular answers to questions about mood and thinking processes on a computer for approximately 5 hours. Blood samples will be taken during this part of the study.

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2004-12-22
Est. Completion 2015-02-27

Why NCT00247689 stopped before completion

NCT00247689 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00247689 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00247689 about?

NCT00247689 is a clinical study titled "Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics". Background: * Research has shown that several human genes have been associated with vulnerability to substance abuse and dependence. However, little is known about how people with these genetic tendencies react to drugs in controlled settings. * Methylphenidate, also known as Ritalin, is commonly p...

What is the current status of trial NCT00247689?

This trial is currently terminated. The enrollment target is 31 participants. The study started on 2004-12-22. Estimated completion is 2015-02-27.

Who is sponsoring clinical trial NCT00247689?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00247689, the US trial registry maintained by the National Library of Medicine. NCT00247689 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.